Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Pfizer Ltd

₹ 4,746-1.52%
16 Jan 3:40 p.m. – close price
🔗pfizerindia.com•BSE: 500680•NSE: PFIZER
Market Cap₹ 21,712 Cr.
Current Price₹ 4,746
High / Low₹ 5,993
Stock P/E30.7
Book Value₹ 841
Dividend Yield0.73 %
ROCE21.6 %
ROE16.4 %
Face Value₹ 10.0
Sales₹ 2,375 Cr.
OPM34.2 %
Mar Cap₹ 21,712 Cr.

ABOUT

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1]It is the 3rd largest multinational pharmaceutical company in India.[2]

KEY POINTS

ParentageThe company is a subsidiary of Pfizer Inc. one of the world’s leading biopharma companies with a presence in over 125 countries. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.[1][2]

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsCapacity Expansion And ProductsJv Partnerships AcquisitionsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1669.2034.64400497.060.953124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1112.970.07
2.Divi's Lab.6233.9566.60165491.740.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7113.530.01
3.Torrent Pharma.4018.7562.76136012.730.81591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1213.260.33
4.Cipla1399.4020.77113039.590.941353.373.737589.447.6422.7228349.5725.405441.141351.173.3914.720.01
5.Lupin2174.2023.0799317.100.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0812.410.32
6.Dr Reddy's Labs1179.3017.0898427.950.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7412.950.16
7.Mankind Pharma2173.5551.3589725.230.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.968.890.55
8.Pfizer4746.1030.7221712.320.73189.0219.37642.349.1321.622375.2934.25706.70189.025.6514.020.01
–Median: 149 Co.390.630.091763.550.1113.4911.71161.7610.5814.89591.7315.9345.2613.963.078.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
637622573531575540547563589538592603642
Expenses
406418391421393387357385399392364393412
Operating Profit
232203182111183153189177189146228210230
Other Income
2132712333644754243432176742
Profit before tax
415201165126201176244203215172426260255
Tax %
25%25%21%26%26%26%27%26%26%26%22%26%26%
Net Profit
31115113094149130179151158128331192189
EPS in Rs
68.0032.9328.3420.4432.5628.4139.1032.9434.6127.8972.3441.9141.32

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
1,1121,8532,0121,9661,9692,0822,1522,2392,6112,4252,1932,2812,375
Expenses
8721,4381,5791,6161,4681,5161,5781,5261,7751,6161,5551,5401,562
Operating Profit
239414433350501566574712836809638742813
Other Income
10944972321141671838163134185344369
Interest
1212121115111315810
Depreciation
825058636671103109115106626160
Profit before tax
3402074705175486606426697738247461,0161,113
Net Profit
22170305337360429509498613624551768839
EPS in Rs
74.0115.2666.6773.6278.7193.79111.29108.77133.90136.38120.52167.79183.46
Dividend Payout %
486%82%22%27%25%24%297%32%26%51%29%98%–

Compounded Sales Growth

10 Years:2%
5 Years:1%
3 Years:-4%
TTM:6%

Compounded Profit Growth

10 Years:20%
5 Years:5%
3 Years:2%
TTM:15%

Stock Price CAGR

10 Years:8%
5 Years:-1%
3 Years:5%
1 Year:-3%

Return on Equity

10 Years:16%
5 Years:18%
3 Years:17%
Last Year:16%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
30464646464646464646464646
Reserves
6291,9272,1182,3732,6372,9663,3502,3472,8193,1623,5504,1723,803
Borrowings
0222222633941404143
Other Liabilities
3186387228401,0049261,007810997752593653714
Total Liabilities
9772,6142,8883,2613,6903,9404,4053,2663,9014,0014,2294,9114,606
Fixed Assets
20944925902950886973894869749713724701
Gross Block
1151,2899811,0211,1331,1381,3151,3161,3831,3521,3561,418–
Accumulated Depreciation
9534456119182252342422514603643695–
CWIP
313315101318088
Investments
4443370000000000
Other Assets
9091,6141,9232,3432,7393,0543,4322,3693,0303,2443,5164,1803,897
Total Assets
9772,6142,8883,2613,6903,9404,4053,2663,9014,0014,2294,9114,606

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
13211334532933298323427667356257660
Cash from Investing Activity
10368-701-250-238351,530-469-575-3654-71
Cash from Financing Activity
-1,360-1-62-83-110-110-164-1,571-181-346-235-205
Net Cash Flow
-1,125181-417-3-17231,690-1,613-88-2675383

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
573226202930291820233131
Inventory Days
148191167148147189198199173175200214
Days Payable
156165157178245213197130102917768
Cash Conversion Cycle
495836-10-696318791107154177
Working Capital Days
257-9-47-57-16-83-14-42423
ROCE %
29%24%22%17%21%23%20%23%29%26%22%22%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%
FIIs
2.77%2.80%2.81%2.82%3.03%3.32%3.22%3.54%2.74%2.18%2.40%2.60%
DIIs
14.93%14.89%14.89%15.00%15.15%15.32%15.83%16.03%16.80%17.10%17.23%17.11%
Public
18.39%18.38%18.37%18.24%17.87%17.42%17.00%16.50%16.54%16.79%16.45%16.37%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Pfizer Limited Files SEBI Compliance Certificate for Dematerialization

9th April 2026, 11:21 pm

Pfizer Announces Special Window for Share Transfer and Dematerialization

9th April 2026, 1:30 am

Fuel runs low for QSR stock rally

8th April 2026, 6:35 pm

Pfizer Limited Announces Senior Management Changes

1st April 2026, 12:09 am

Pfizer Limited Announces Trading Window Closure for Financial Results

28th March 2026, 8:34 pm

Published by Other Websites

External media mentions & references

US Tariff Threat Hits Indian Pharma Stocks Hard, Index Down 3%

2nd April 2026, 11:10 am

Adobe CEO Narayen's Cloud Pivot: $3B to $21B Revenue Masterclass

25th February 2026, 6:03 pm

Dalal Street Pain: Stock Picking Hits Rough Patch, Most Stocks Underperform

14th February 2026, 10:38 pm

Pfizer India's Margin Leap Fuels Rally; Sustainability Questioned

10th February 2026, 12:05 pm

Pfizer Shares Surge 11% on Strong Q3 Results, New Migraine Drug Boosts Outlook

10th February 2026, 11:11 am

News Articles

Editorial & research coverage

India Stocks: Index Up, Individual Shares Down - The Divergence Deepens
India Stocks: Index Up, Individual Shares Down - The Divergence Deepens

14th February 2026, 10:38 pm

Pfizer India's Margin Leap Fuels Rally; Sustainability Questioned
Pfizer India's Margin Leap Fuels Rally; Sustainability Questioned

10th February 2026, 12:05 pm

Pfizer Shares Surge 11% on Strong Q3 Results, New Migraine Drug Boosts Outlook
Pfizer Shares Surge 11% on Strong Q3 Results, New Migraine Drug Boosts Outlook

10th February 2026, 11:11 am

Pfizer India's Margin Leap Fuels Q3 Profit Surge
Pfizer India's Margin Leap Fuels Q3 Profit Surge

9th February 2026, 8:47 pm

Nifty SmallCap Flags Bearish Death Cross; 132 Stocks Follow Suit
Nifty SmallCap Flags Bearish Death Cross; 132 Stocks Follow Suit

12th January 2026, 11:54 am

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

9 Jan - Certificate confirming compliance with Regulation 74(5) of the SEBI (DP) Regulations, 2018, for the quarter ended December, 31, 2025.

Closure of Trading Window
Disclosure under Regulation 30A of LODR

28 Dec - Received Dec 27, 2025 GST order: tax Rs4,39,55,698 + penalty Rs4,39,55,698; total Rs8,79,11,396; appeal planned.

Intimation Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015.

24 Dec - GST order dated Dec 23, 2025 for Rs1,26,87,141; Pfizer to appeal; no material impact.

Announcement under Regulation 30 (LODR)-Change in Management

23 Dec - Aditi Mehta resigns as Category Lead – Vaccines, effective January 2, 2026.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from nse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Credit Ratings

No credit ratings.

Concalls

Aug 2020

Transcript

May 2017

Transcript

Feb 2017

Transcript

Nov 2016

Transcript

Aug 2016

Transcript

May 2016

Transcript

Feb 2016

Transcript

Stock Analysis

Description

  1. Pfizer Ltd is engaged in manufacturing, marketing, trading, and export of pharmaceutical products, operating through its own facilities and third-party manufacturers, primarily selling its products through distributors in India. It is a subsidiary of Pfizer Inc., a global biopharmaceutical leader.

Key Growth Triggers

  1. Launch of the PCV20 vaccine for adults aims to capture a new market segment and address unmet needs in adult immunization.
  2. Strategic 5-year distribution partnership with Cipla leverages Cipla's extensive network to increase market penetration for key Pfizer brands.
  3. The company's strong financial performance in Q2 FY26, with significant YoY growth in revenue and net profit, indicates operational momentum.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. The company has historically delivered poor sales growth (1.18% over the last five years, according to company data).
  2. Received GST demand and penalty orders totaling approximately ₹10.05 crore, although the company stated no material impact.
  3. Resignation of Ms. Aditi Mehta, Category Lead – Vaccines, effective January 2, 2026, noted as a change in key personnel.

Key Dates To Watch

  1. Board meeting to approve Q2 FY26 financial results held on November 12, 2025.
  2. Effective date for Ms. Aditi Mehta's resignation: January 2, 2026.

Corporate Announcements

9th Apr 26
Impact Rating: 3
Pfizer Limited's Registrar confirmed adherence to SEBI (Depositories and Participants) Regulations, 2018, for share dematerialization actions during the quarter ended March 31, 2026.
8th Apr 26
Impact Rating: -
No description available.
8th Apr 26
Impact Rating: -
No description available.
31st Mar 26
Impact Rating: 5
Pfizer Limited has reported changes in its Senior Management Personnel. Mr. Deepak Rakheja's resignation is effective July 8, 2026, for opportunities outside the company. Mr. Anil Pattanshetty will transition to another group company on April 1, 2026.
28th Mar 26
Impact Rating: 6
Pfizer Limited will close its trading window starting March 31, 2026, until 48 hours post-results announcement. This is for the declaration of financial results for the quarter and fiscal year ending March 31, 2026.